April 10, 2007
North America - East
$EUSA Pharma and $AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib) t.co/m8eAfVE6xI
$AVEO Reports 3Q17 Financial Results and Provides Business Update t.co/QxQ3WqPUSt
$AVEO & $EUSA Pharma Announce Promising Ph 1 Results from the Ph 1/2 TiNivo Study of Tivozanib & Nivolumab in #RCC t.co/yhDK5bu7CH
$AVEO Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium t.co/iLBjZfrXs1
Aveo Pharmaceuticals integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics.